Total Funding
24
42
Total FundingVenture - Series Unknown raised
Growth Score 24 in past quarter
-1 pts
Heat Score 42 in past quarter
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
41947
PierianDx is catalyzing global adoption of genomic sequencing in healthcare
Acquired by 

Summa Equity
- Shubham Aher: Team Lead (Product Development - L3)
Mark McDonough: President and CEOPast Role: CombiMatrix, Chief Commercial Officer
About the Company
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases. PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health
systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum. From genomic sequencing and biomedical informatics in the laboratory to reporting and decision support at the patient’s bedside, PierianDx has rapidly become the trusted source of ‘wisdom’ in every advanced genomic report.
